Pipeline
ADC와 합성신약 분야에 혁신적이고 독창적인 파이프라인을 보유하고 있습니다.
Our Pipeline
항생제
| Program | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketed | Partner | Details |
|---|---|---|---|---|---|---|---|---|---|
| Delpazolid 그람양성균 |
-일반 결핵 -다제내성 결핵 -MRSA / VRE -NTM |
|
|
- Orphan Drug |
|||||
|
|
|
- L/O for China |
|||||||
항섬유화제
| Program | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketed | Partner | Details |
|---|---|---|---|---|---|---|---|---|---|
| LCB17-0877 ATX 저해제 |
특발성폐섬유증 |
|
|
-L/O for global |
|||||
항응혈제
| Program | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketed | Partner | Details |
|---|---|---|---|---|---|---|---|---|---|
| LCB02-0133 Nokxaban,FXa Inhibitor |
|
|
L/O for global (Profit Sharing) |
||||||
|
|
|
Sub L/O for China |
|||||||
Immuno Oncology
| Program | Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketed | Partner | Details |
|---|---|---|---|---|---|---|---|---|---|
| LCB39 STING agonist |
|
|
- I/O Targeted |
||||||
| LCB33 ENPP1 inhibitor |
|
|
-Combi with ADCs |
||||||